FGI-106 tetrahydrochloride
CAS No. 1149348-10-6
FGI-106 tetrahydrochloride ( —— )
Catalog No. M26214 CAS No. 1149348-10-6
FGI-106 tetrahydrochloride is active against Ebola, Rift Valley and Dengue Fever viruses with EC50s of 100 nM, 800 nM and 400-900 nM, respectively.?
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 260 | Get Quote |
|
10MG | 410 | Get Quote |
|
25MG | 678 | Get Quote |
|
50MG | 954 | Get Quote |
|
100MG | 1287 | Get Quote |
|
200MG | Get Quote | Get Quote |
|
500MG | Get Quote | Get Quote |
|
1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameFGI-106 tetrahydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionFGI-106 tetrahydrochloride is active against Ebola, Rift Valley and Dengue Fever viruses with EC50s of 100 nM, 800 nM and 400-900 nM, respectively.?
-
DescriptionFGI-106 tetrahydrochloride is active against Ebola, Rift Valley and Dengue Fever viruses with EC50s of 100 nM, 800 nM and 400-900 nM, respectively.?FGI-106 tetrahydrochloride also inhibits non-hemorrhagic fever viruses HCV and HIV-1 with EC50s of 200 nM and 150 nM, respectively.?FGI-106 tetrahydrochloride is a potent and broad-spectrum inhibitor with inhibitory activity against multiple viruses.(In Vitro):In cell-based assays, treatment with FGI-106 inhibits viral replication by divergent virus families, including positive and negative-strand RNA viruses.Treatment with 2 μM FGI-106 mediated a 4 log reduction in infectious viral titers relative to matched controls, with an EC90 for inhibition of viral killing of host cells (Vero E6 cells) estimated to be 0.6 μM.?(In Vivo):FGI-106??treatment decreases mortality from Zaire EBOV in a dose-dependent manner.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1149348-10-6
-
Formula Weight604.5
-
Molecular FormulaC28H42Cl4N6
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCl.Cl.Cl.Cl.CN(C)CCCNc1cc(C)nc2c1ccc1c2ccc2c(NCCCN(C)C)cc(C)nc12
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Bodner et al (2006) Pharmacological promotion of inclusion formation:a therapeutic approach for Huntington's and Parksinson's diseases. Proc.Natl.Acad.Sci.USA 103 4246
molnova catalog
related products
-
Arctigenin 4-O-beta-...
Arctigenin 4'-O-beta-gentiobioside is a natural product from Trachelospermum jasminoides.
-
[Glu1]-Fibrinopeptid...
[Glu1]-Fibrinopeptide B is derived from fibrinopeptide B amino acid residues 1-14. Human fibrinopeptide B (hFpB), a thrombin-derived proteolytic cleavage product of the fibrinogen B beta-chain, to stimulate neutrophils (PMN), monocytes, and fibroblasts.
-
CPD77
CPD77 is a potent SARS-?CoV-?2 main protease inhibitor.?